ArticleMolecular therapy. Methods & clinical development2025
Generation of high-quality single-stranded DNA for full-length and truncated genome standards of recombinant adeno-associated viruses.
Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- It's what's on the inside that counts: Capsid content as a critical quality attribute for AAV characterization.Molecular therapy. Advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The integrity of the single-stranded DNA (ssDNA) genome of recombinant adeno-associated viral vectors (rAAVs) for gene therapy applications is a critical quality attribute. To monitor this attribute, robust analytical methods, such as long-read sequencing or multiplex PCR, are needed. Due to the heterogeneity of the packaged rAAV payloads, the availability of appropriate ssDNA standards could clearly facilitate the development of these methods and may be used for system suitability testing. However, due to a genome length of up to approximately 4.7 kilobases and the secondary structure of the inverted terminal repeats, such standards are not trivial to produce. Here, we introduce a versatile method that starts with plasmid DNA containing the rAAV genome of interest. After its linearization, the sticky ends are filled in with biotinylated deoxynucleotide triphosphates, and the DNA is bound to streptavidin-coupled beads. With two further restriction enzymes, the plasmid backbone is removed, and finally, the ssDNA is obtained by alkaline strand separation. The quality and purity of the received ssDNA were verified using double-strand synthesis followed by size determination and long-read sequencing. With the presented method, it is possible to generate both full-length and truncated ssDNA standards within one day, contributing to improved quality control of rAAVs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.